Gender differences in Parkinson's disease

Clinical Neuropharmacology

Volumn 21, Issue 2, 1998, Pages 118-121

  Lyons, Kelly E ^a   Hubble, Jean P ^a,b   Tröster, Alexander I ^a   Pahwa, Rajesh ^a   Koller, William C ^a  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

Estrogen; Gender; Parkinson's disease

Indexed keywords

ESTROGEN; LEVODOPA;

ADULT; AGE; AGED; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DISEASE COURSE; DISEASE DURATION; DYSKINESIA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PARKINSON DISEASE; PRIORITY JOURNAL; SEX DIFFERENCE; TREMOR;

AGED; COHORT STUDIES; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MOTOR ACTIVITY; NEUROBEHAVIORAL MANIFESTATIONS; PARKINSON DISEASE; SEX FACTORS;

EID: 0031954286     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Mutch WJ, Dingwall-Fordyce I, Downie AW, Paterson JG, Roy SK. Parkinson's disease in a Scottish city. Br Med J 1986;292:534-6.
2. Tanner CM. Epidemiology of movement disorders. In: Anderson DW, ed. Neuroepidemiology: a tribute to Bruce Schoenberg. Boca Raton, FL: CRC Press, 1991:193-216.
3. Mayeux R, Denaro J, Henenegildo N, et al. A population-based investigation of Parkinson's disease with and without dementia. Relationship to age and gender. Arch Neurol 1992;49:492-7.
4. Quinn NP, Marsden CD. Menstrual-related fluctuations in Parkinson's disease. Mov Disord 1986;1:85-6.
5. Mizuta E, Yamasaki S, Nakatake M, Kuno S. Neuroleptic malignant syndrome in a parkinsonian woman during the premenstrual period. Neurology 1993;43:1048-9.
6. Fahn S, Elton RL, UPDRS Development Committee. Unified Parkinson's disease rating scale. In: Fahn S, Marsden CD, Calne D, Goldstein M, eds. Recent developments in Parkinson's disease, vol 2. Florham Park, NY: MacMillan Healthcare Information, 1987:153-63, 293-304.
7. Folstein MF, Folstein SE, McHugh PA. Mini-Mental State: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-98.
8. Cagnacci A, Melis GB, Soldani R, et al. Altered neuroendocrine regulation of luteinizing hormone secretion in postmenopausal women with Parkinson's disease. Neuroendocriology 1991;53:549-55.
9. Thulin PC, Carter JH, Nichols MD, Kurth M, Nutt JG. Menstrual-cycle related changes in Parkinson's disease [Abstract]. Neurology 1996;46:376.
10. Weiner WJ, Shulman LM, Singer C, Leifert R, Mash D. Menopause and estrogen replacement therapy in Parkinson's disease [Abstract]. Neurology 1996;46:376.
11. Session DR, Pearlstone MM, Jewelewicz R, Kelly AC. Estrogens and Parkinson's disease. Med Hypoth 1994;42:280-2.
12. Villeneuve A, Cazejust T, Cote M. Estrogens in tardive dyskinesia in male psychiatric patients. Neuropsychobiology 1980;6:145-51.
13. Bedard P, Langelier P, Villeneuve A. Oestrogens and extrapyramidal system. Lancet 1977;2:1367-8.
14. Fields JZ, Gordon JH. Estrogen inhibits the dopaminergic supersensitivity induced by neuroleptics. Life Sci 1982;30:229-34.
15. Hruska RE, Silbergeld. Increased dopamine receptor sensitivity after estrogen treatment using the rat rotation model. Science 1980;208:1466-8.
16. Parkinson's Study Group. Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP patients requiring levodopa. Ann Neurol 1996;39:37-45.